{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:19Z","timestamp":1792801639413,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1038\/s41591-019-0560-x","type":"journal-article","created":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T12:04:05Z","timestamp":1568030645000},"page":"1377-1384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":172,"title":["A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model"],"prefix":"10.1038","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4444-7483","authenticated-orcid":false,"given":"Stephen R.","family":"Yant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mulato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winston C.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Niedziela-Majka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Stepan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie H.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill M.","family":"Perreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe A.","family":"Papalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Y.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shekeba","family":"Ahmadyar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Liclican","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Novikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Paoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gonik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee R.","family":"Ram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdeleine","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William M.","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham L.","family":"Brass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley I.","family":"Sundquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Cihlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John O.","family":"Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,9]]},"reference":[{"key":"560_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13548506.2014.945601","volume":"20","author":"KR Claborn","year":"2015","unstructured":"Claborn, K. R., Meier, E., Miller, M. B. & Leffingwell, T. R. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy. Psychol. Health Med. 20, 1\u201311 (2015).","journal-title":"Psychol. Health Med."},{"key":"560_CR2","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.2147\/PPA.S141762","volume":"11","author":"J Boretzki","year":"2017","unstructured":"Boretzki, J. et al. Highly specific reasons for nonadherence to antiretroviral therapy: results from the german adherence study. Patient Prefer. Adherence 11, 1897\u20131906 (2017).","journal-title":"Patient Prefer. Adherence"},{"key":"560_CR3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/QAI.0000000000000880","volume":"71","author":"A Corneli","year":"2016","unstructured":"Corneli, A. et al. Participants\u2019 explanations for nonadherence in the FEM-PrEP clinical trial. J. Acquir. Immune Defic. Syndr. 71, 452\u2013461 (2016).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"560_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11904-017-0353-0","volume":"14","author":"AN Nyaku","year":"2017","unstructured":"Nyaku, A. N., Kelly, S. G. & Taiwo, B. O. Long-acting antiretrovirals: Where are we now? Curr. HIV\/AIDS Rep. 14, 63\u201371 (2017).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"560_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.coph.2010.04.011","volume":"10","author":"E De Clercq","year":"2010","unstructured":"De Clercq, E. Antiretroviral drugs. Curr. Opin. Pharmacol. 10, 507\u2013515 (2010).","journal-title":"Curr. Opin. Pharmacol."},{"key":"560_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.2174\/1570162X14999160224103555","volume":"14","author":"S Thenin-Houssier","year":"2016","unstructured":"Thenin-Houssier, S. & Valente, S. T. HIV-1 Capsid inhibitors as antiretroviral agents. Curr. HIV Res. 14, 270\u2013282 (2016).","journal-title":"Curr. HIV Res."},{"key":"560_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/COH.0000000000000472","volume":"13","author":"SK Carnes","year":"2018","unstructured":"Carnes, S. K., Sheehan, J. H. & Aiken, C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS 13, 359\u2013365 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"560_CR8","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrmicro3490","volume":"13","author":"EO Freed","year":"2015","unstructured":"Freed, E. O. HIV-1 Assembly, release and maturation. Nat. Rev. Microbiol. 13, 484\u2013496 (2015).","journal-title":"Nat. Rev. Microbiol."},{"key":"560_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.283.5398.80","volume":"283","author":"BK Ganser","year":"1999","unstructured":"Ganser, B. K., Li, S., Klishko, V. Y., Finch, J. T. & Sundquist, W. I. Assembly and analysis of conical models for the HIV-1 core. Science 283, 80\u201383 (1999).","journal-title":"Science"},{"key":"560_CR10","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.1128\/JVI.76.11.5667-5677.2002","volume":"76","author":"BM Forshey","year":"2002","unstructured":"Forshey, B. M., von Schwedler, U., Sundquist, W. I. & Aiken, C. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol. 76, 5667\u20135677 (2002).","journal-title":"J. Virol."},{"key":"560_CR11","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.tim.2017.04.004","volume":"25","author":"M Yamashita","year":"2017","unstructured":"Yamashita, M. & Engelman, A. N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol. 25, 741\u2013755 (2017).","journal-title":"Trends Microbiol."},{"key":"560_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1001220","volume":"6","author":"WS Blair","year":"2010","unstructured":"Blair, W. S. et al. HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 6, 1\u201310 (2010).","journal-title":"PLoS Pathog."},{"key":"560_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cell.2009.04.063","volume":"137","author":"O Pornillos","year":"2009","unstructured":"Pornillos, O. et al. X-ray structures of the hexameric building block of the HIV Capsid. Cell 137, 1\u201321 (2009).","journal-title":"Cell"},{"key":"560_CR14","doi-asserted-by":"publisher","first-page":"18625","DOI":"10.1073\/pnas.1419945112","volume":"111","author":"A Bhattacharya","year":"2014","unstructured":"Bhattacharya, A. et al. Structural basis of HIV-1 Capsid recognition by PF74 and CPSF6. Proc. Natl. Acad. Sci. USA 111, 18625\u201318630 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"560_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1003693","volume":"9","author":"KA Matreyek","year":"2013","unstructured":"Matreyek, K. A., Yucel, S. S., Li, X. & Engelman, A. Nucleoporin NUP153 phenylalanine-glycine motifs engage a common binding pocket within the HIV-1 Capsid protein to mediate lentiviral infectivity. PLoS Pathog. 9, 1\u201321 (2013).","journal-title":"PLoS Pathog."},{"key":"560_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1002896","volume":"8","author":"AJ Price","year":"2012","unstructured":"Price, A. J. et al. CPSF6 defines a conserved capsid interface that modulates HIV-1 replication. PLoS Pathog. 8, 1\u201314 (2012).","journal-title":"PLoS Pathog."},{"key":"560_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1004459","volume":"10","author":"AJ Price","year":"2014","unstructured":"Price, A. J. et al. Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly. PLoS Pathog. 10, 1\u201317 (2014).","journal-title":"PLoS Pathog."},{"key":"560_CR18","doi-asserted-by":"crossref","first-page":"4874","DOI":"10.1128\/JVI.66.8.4874-4883.1992","volume":"66","author":"LS Ehrlich","year":"1992","unstructured":"Ehrlich, L. S., Agresta, B. E. & Carter, C. A. Assembly of recombinant human immunodeficiency virus type 1 capsid protein in vitro. J. Virol. 66, 4874\u20134883 (1992).","journal-title":"J. Virol."},{"key":"560_CR19","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cell.2007.08.018","volume":"131","author":"BK Ganser-Pornillos","year":"2007","unstructured":"Ganser-Pornillos, B. K., Cheng, A. & Yeager, M. Structure of full-length HIV-1 CA: A model for the mature capsid lattice. Cell 131, 70\u201379 (2007).","journal-title":"Cell"},{"key":"560_CR20","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1128\/JVI.78.5.2545-2552.2004","volume":"78","author":"BK Ganser-Pornillos","year":"2004","unstructured":"Ganser-Pornillos, B. K., von Schwedler, U. K., Stray, K. M., Aiken, C. & Sundquist, W. I. Assembly properties of the human immunodeficiency virus type 1 CA protein. J. Virol. 78, 2545\u20132552 (2004).","journal-title":"J. Virol."},{"key":"560_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/35030177","volume":"407","author":"S Li","year":"2000","unstructured":"Li, S., Hill, C. P., Sundquist, W. I. & Finch, J. T. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407, 409\u2013413 (2000).","journal-title":"Nature"},{"key":"560_CR22","first-page":"1","volume":"8","author":"M Hung","year":"2013","unstructured":"Hung, M. et al. Large-scale functional purification of recombinant HIV-1 Capsid. PLoS ONE 8, 1\u201311 (2013).","journal-title":"PLoS ONE"},{"key":"560_CR23","doi-asserted-by":"publisher","first-page":"e74163","DOI":"10.1371\/journal.pone.0074163","volume":"8","author":"M Balakrishnan","year":"2013","unstructured":"Balakrishnan, M. et al. Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS ONE 8, e74163 (2013).","journal-title":"PLoS ONE"},{"key":"560_CR24","doi-asserted-by":"publisher","first-page":"e1002194","DOI":"10.1371\/journal.ppat.1002194","volume":"7","author":"L Zhou","year":"2011","unstructured":"Zhou, L. et al. Transportin 3 promotes a nuclear maturation step required for efficient HIV-1 integration. PLoS Pathog. 7, e1002194 (2011).","journal-title":"PLoS Pathog."},{"key":"560_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-016-0262-0","volume":"13","author":"NY Chen","year":"2016","unstructured":"Chen, N. Y. et al. HIV-1 capsid is involved in post-nuclear entry steps. Retrovirology 13, 28 (2016).","journal-title":"Retrovirology"},{"key":"560_CR26","doi-asserted-by":"publisher","first-page":"e01741","DOI":"10.1128\/JVI.01741-18","volume":"93","author":"M Balasubramaniam","year":"2018","unstructured":"Balasubramaniam, M. et al. PF74 Inhibits HIV-1 integration by altering the composition of the preintegration complex. J. Virol. 93, e01741\u201318 (2018).","journal-title":"J. Virol."},{"key":"560_CR27","doi-asserted-by":"publisher","first-page":"e04114","DOI":"10.7554\/eLife.04114","volume":"3","author":"K Peng","year":"2014","unstructured":"Peng, K. et al. Quantitative microscopy of functional HIV post-entry complexes reveals association of replication with the viral capsid. eLife 3, e04114 (2014).","journal-title":"eLife"},{"key":"560_CR28","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1128\/JVI.00476-15","volume":"89","author":"AE Hulme","year":"2015","unstructured":"Hulme, A. E., Kelley, Z., Foley, D. & Hope, T. J. Complementary assays reveal a low level of CA associated with viral complexes in the nuclei of HIV-1-infected cells. J. Virol. 89, 5350\u20135361 (2015).","journal-title":"J. Virol."},{"key":"560_CR29","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.celrep.2015.10.036","volume":"13","author":"CR Chin","year":"2015","unstructured":"Chin, C. R. et al. Direct visualization of HIV-1 replication intermediates shows that capsid and cpsf6 modulate hiv-1 intra-nuclear invasion and integration. Cell Rep. 13, 1717\u20131731 (2015).","journal-title":"Cell Rep."},{"key":"560_CR30","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/COH.0000000000000474","volume":"13","author":"F Ferretti","year":"2018","unstructured":"Ferretti, F. & Boffito, M. Rilpivirine long-acting for the prevention and treatment of HIV infection. Curr. Opin. HIV AIDS 13, 300\u2013307 (2018).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"560_CR31","unstructured":"Sager, J. E. et al. Safety and PK of subcutaneous GS-6207, a novel HIV-1 capsid inhibitor. in Conference on Retroviruses and Opportunistic Infections (CROI), abstr. 141 (2019)."},{"key":"560_CR32","unstructured":"Daar, E. S. et al. Safety and antiviral activity over 10 days following a single dose of subcutaneous GS-6207, a first-in-class, long-acting HIV capsid inhibitor for people living with HIV. in IAS Conference on HIV Science, abstr. 4906 (2019)."},{"key":"560_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1006\/viro.2000.0780","volume":"280","author":"C Spenlehauer","year":"2001","unstructured":"Spenlehauer, C., Gordon, C. A., Trkola, A. & Moore, J. P. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. Virology 280, 292\u2013300 (2001).","journal-title":"Virology"},{"key":"560_CR34","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang, M. et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob. Agents Chemother. 60, 7086\u20137097 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"560_CR35","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1089\/aid.2015.0074","volume":"31","author":"MO Alberti","year":"2015","unstructured":"Alberti, M. O. et al. Optimized replicating renilla luciferase reporter HIV-1 utilizing novel internal ribosome entry site elements for native Nef expression and function. AIDS Res. Hum. Retrovir. 31, 1278\u20131296 (2015).","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"560_CR36","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1128\/AAC.01784-09","volume":"54","author":"NA Margot","year":"2010","unstructured":"Margot, N. A., Gibbs, C. S. & Miller, M. D. Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat. Antimicrob. Agents Chemother. 54, 2345\u20132353 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"560_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nature09640","volume":"469","author":"O Pornillos","year":"2011","unstructured":"Pornillos, O., Ganser-Pornillos, B. K. & Yeager, M. Atomic-level modelling of the HIV capsid. Nature 469, 424\u2013427 (2011).","journal-title":"Nature"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0560-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0560-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:00:03Z","timestamp":1684605603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0560-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["560"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0560-x","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736581505.793565575","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"27 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are current or previous employees of Gilead Sciences (except W.I.S., W.M.M., J.M.P. and A.L.B.) and have received a salary and stock ownership as compensation for their employment. J.O.L., S.D.S., W.C.T. and J.R.Z. are inventors on granted US Patent No. 10,071,985 covering GS-CA1 composition of matter and methods of use.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}